Company Monitoring Page for Sanofi

latest headlines for company on cafepharma

Merck treads on Sanofi, Regeneron's turf with Keytruda's latest skin cancer OK
Fierce Pharma
Wed, 06/24/20 - 11:41 pm
Tags:
Merck, Keytruda, FDA, squamous cell carcinoma, Sanofi, Regeneron, Libtayo
Sanofi's fight for a better research reputation
BioPharma Dive
Tue, 06/23/20 - 11:34 pm
Tags:
Sanofi, R&D, cancer, immune disorders
Sanofi’s third Translate collaboration sees big bucks at last
EP Vantage
Tue, 06/23/20 - 10:44 am
Tags:
Sanofi, vaccines, Translate Bio, MRNA
Third-quarter events to watch for large drug makers
EP Vantage
Mon, 06/22/20 - 10:35 am
Tags:
Biogen, aducanumab, Sanofi, THOR-707, Bristol-Myers Squibb, pegbelfermin, Eli Lilly, FDA
Sanofi, Regeneron Win China Approval For Dupixent Dermatitis Drug
Yahoo/SmarterAnalyst
Mon, 06/22/20 - 10:30 am
Tags:
Sanofi, Regeneron, China, Dupixent, atopic dermatitis
Amicus shares surge as Sanofi struggles to raise a cheer for mixed pivotal data for a PhIII contender — and analysts blow a raspberry
Endpoints
Wed, 06/17/20 - 10:07 pm
Tags:
Sanofi, Amicus Therapeutics, clinical trials, Pompe disease, Avalglucosidase alfa, Lumizyme
Sanofi pumps $554M into new vaccine manufacturing facility in eastern France
Fierce Pharma
Tue, 06/16/20 - 10:54 am
Tags:
Sanofi, vaccines, drug manufacturing, France
ADA: Sanofi bolsters Soliqua with real-world data showing starting insulin, GLP-1 together helps control blood sugar
Fierce Pharma
Sun, 06/14/20 - 08:06 pm
Tags:
ADA, diabetes, Sanofi, Soliqua, type 2 diabetes
ADA: Novo Nordisk's long-lasting insulin candidate matches Lantus in phase 2
Fierce Pharma
Sun, 06/14/20 - 08:05 pm
Tags:
ADA, diabetes, Novo Nordisk, insulin icodec, Sanofi, Lantus, insulin
Mylan and Biocon Gain FDA Approval for Insulin Equivalent to Sanofi's Lantus
Motley Fool
Fri, 06/12/20 - 08:03 pm
Tags:
FDA, Mylan, Biocon, Semglee, Sanofi, insulin, Lantus, diabetes
AAD 2020 – Leo’s eczema wildcard proves tame
EP Vantage
Fri, 06/12/20 - 08:02 pm
Tags:
LEO Pharma, Sanofi, Regeneron, eczema, atopic dermatitis, AAD, tralokinumab
After Disappointing Study Results, Denali and Sanofi Shift Resources to a Different Alzheimer's Drug
BioSpace
Thu, 06/11/20 - 10:49 pm
Tags:
Denali Therapeutics, Sanofi, DNL747, ALS, Alzheimer's disease, DNL788, clinical trials
Sanofi sharpens focus on bispecifics, and China, with Alphamab deal
Endpoints
Wed, 06/10/20 - 10:41 am
Tags:
Sanofi, China, Alphamab Oncology, breast cancer, bispecific antibodies
The coronavirus vaccine frontrunners have emerged. Here's where they stand
BioPharma Dive
Tue, 06/9/20 - 12:32 pm
Tags:
COVID-19, vaccines, Moderna Therapeutics, Cansino Biologics, Pfizer, BioNTech, Novavax, Inovio, Oxford BioMedica, AstraZeneca, Merck, JNJ, Sanofi, GSK
After 11 years, Sanofi kicks backs the rights to unwanted gene therapies to Oxford Biomedica
Fierce Biotech
Mon, 06/8/20 - 11:32 pm
Tags:
Oxford BioMedica, Sanofi
Is Moderna Really the Leader in the COVID-19 Vaccine Race?
Motley Fool
Mon, 06/8/20 - 10:35 am
Tags:
vaccines, COVID-19, Moderna Therapeutics, AstraZeneca, Pfizer, JNJ, BioNTech, Merck, Sanofi, GSK, Novavax, Inovio
Sanofi loses vaccines chief Loew to Ipsen amid global attention on its COVID-19 project
Fierce Pharma
Fri, 05/29/20 - 12:27 pm
Tags:
Sanofi, Paul Hudson, David Loew, Ipsen, Pharma CEOs, FerGene, vaccines
GlaxoSmithKline aims to make 1B doses of vaccine booster for multiple COVID-19 partners
Fierce Pharma
Thu, 05/28/20 - 10:56 am
Tags:
GSK, vaccines, COVID-19, drug manufacturing, Sanofi, pandemic
What Sanofi Might Buy With Its Regeneron Windfall
Barron's
Wed, 05/27/20 - 11:01 am
Tags:
Sanofi, Regeneron, M&A, gene therapy, Ultragenyx, Bluebird Bio
Sanofi and Regeneron's Dupixent Scores Another Approval for Dermatitis, This Time in Kids
BioSpace
Wed, 05/27/20 - 10:47 am
Tags:
Sanofi, Regeneron, Dupixent, atopic dermatitis, pediatric

Pages

last 30 twitter posts

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.